66 related articles for article (PubMed ID: 25450283)
1. Association between P-glycoprotein expression and response to chemotherapy in patients with osteosarcoma: a systematic and meta-analysis.
Zhao ZG; Ding F; Liu M; Ma DZ; Zheng CK; Kan WS
J Cancer Res Ther; 2014 Nov; 10 Suppl():C206-9. PubMed ID: 25450283
[TBL] [Abstract][Full Text] [Related]
2. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study.
Pösl M; Amling M; Grahl K; Hentz M; Ritzel H; Werner M; Winkler K; Delling G
Gen Diagn Pathol; 1997 Jun; 142(5-6):317-25. PubMed ID: 9228255
[TBL] [Abstract][Full Text] [Related]
4. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
5. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance and malignancy in human osteosarcoma.
Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N
Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324
[TBL] [Abstract][Full Text] [Related]
7. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
[TBL] [Abstract][Full Text] [Related]
8. [P-glycoprotein expression in osteosarcoma].
Pösl M; Grahl K; Amling M; Werner M; Ritzel H; Stenzel I; Hentz M; Winkler K; Delling G
Pathologe; 1996 Jan; 17(1):50-5. PubMed ID: 8685096
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
[TBL] [Abstract][Full Text] [Related]
10. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
12. Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.
Li JZ; Tian ZQ; Jiang SN; Feng T
Genet Mol Res; 2014 Apr; 13(2):3186-92. PubMed ID: 24841650
[TBL] [Abstract][Full Text] [Related]
13. Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis.
Wang W; Wang ZC; Shen H; Xie JJ; Lu H
Eur Rev Med Pharmacol Sci; 2014; 18(9):1383-90. PubMed ID: 24867518
[TBL] [Abstract][Full Text] [Related]
14. Multiple drug resistance in osteosarcoma.
Rosier RN; Teot LA; Hicks DG; Schwartz C; O'Keefe RJ; Puzas JE
Iowa Orthop J; 1995; 15():66-73. PubMed ID: 7634047
[No Abstract] [Full Text] [Related]
15. Expression of 11β-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: potential role in pathogenesis and as targets for treatments.
Patel P; Hardy R; Sumathi V; Bartle G; Kindblom LG; Grimer R; Bujalska I; Stewart PM; Rabbitt E; Gittoes NJ; Cooper MS
Endocr Relat Cancer; 2012 Aug; 19(4):589-98. PubMed ID: 22719058
[TBL] [Abstract][Full Text] [Related]
16. [Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients].
Nathrath M; Kremer M; Letzel H; Remberger K; Höfler H; Ulle T
Klin Padiatr; 2002; 214(4):230-5. PubMed ID: 12165907
[TBL] [Abstract][Full Text] [Related]
17. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
18. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo.
Suto R; Abe Y; Nakamura M; Ohnishi Y; Yoshimura M; Lee YH; Imanishi T; Yamazaki H; Kijima H; Tokunaga T; Oshika Y; Hiraoka N; Tamaoki N; Fukuda H; Ueyama Y
Int J Oncol; 1998 Feb; 12(2):287-91. PubMed ID: 9458350
[TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
